

Antonio M Grimaldi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2454855/publications.pdf>

Version: 2024-02-01

23
papers

1,934
citations

687363

13
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

4067
citing authors

#	ARTICLE	IF	CITATIONS
1	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. <i>Journal of Translational Medicine</i> , 2021, 19, 17.	4.4	6
2	Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. <i>Cancers</i> , 2021, 13, 1857.	3.7	5
3	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncolmunology</i> , 2018, 7, e1405206.	4.6	43
4	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. <i>BioDrugs</i> , 2017, 31, 51-61.	4.6	46
5	A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. <i>Melanoma Research</i> , 2017, 27, 243-250.	1.2	12
6	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. <i>Oncolmunology</i> , 2017, 6, e1261242.	4.6	59
7	Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. <i>Melanoma Management</i> , 2015, 2, 209-215.	0.5	7
8	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	4.4	2
9	Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients. <i>Journal of Translational Medicine</i> , 2015, 13, O8.	4.4	2
10	Vemurafenib beyond progression in a patient with metastatic melanoma. <i>Anti-Cancer Drugs</i> , 2015, 26, 464-468.	1.4	2
11	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>Oncolmunology</i> , 2015, 4, e1008842.	4.6	72
12	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmunology</i> , 2014, 3, e28780.	4.6	318
13	Novel Approaches in Melanoma Prevention and Therapy. <i>Cancer Treatment and Research</i> , 2014, 159, 443-455.	0.5	36
14	The role of MEK inhibitors in the treatment of metastatic melanoma. <i>Current Opinion in Oncology</i> , 2014, 26, 196-203.	2.4	39
15	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	4.2	230
16	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127.	2.8	149
17	Marker Utility for Combination Therapy. <i>Methods in Molecular Biology</i> , 2014, 1102, 97-115.	0.9	0
18	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. <i>Clinical Cancer Research</i> , 2013, 19, 997-1008.	7.0	161

#	ARTICLE	IF	CITATIONS
19	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. <i>Journal of Translational Medicine</i> , 2012, 10, 107.	4.4	112
20	Lean oncology: a new model for oncologists. <i>Journal of Translational Medicine</i> , 2012, 10, 74.	4.4	11
21	The role of BRAF V600 mutation in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 85.	4.4	563
22	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8573-8573.	1.6	13
23	Clinical results of EGFR-targeted therapies in advanced colorectal cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 64-69.	2.2	1